Ginkgo bioworks stocks.
Under the terms of the merger agreement entered into on July 24, 2022, Zymergen stockholders received, for each share of Zymergen common stock, 0.9179 shares of Ginkgo Class A common stock. Zymergen shares will no longer be traded on Nasdaq. GinkgoClass A common stock will continue to trade on NYSE under the ticker symbol DNA.
Ginkgo Bioworks Holdings, Inc. Class A Common Stock (DNA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations. 8,194,680. Aug 04 05:01 PM. open in yahoo open in reuters | open in marketwatch open in google open in EDGAR. DNA - Ginkgo Bioworks Holdings Inc - Stock screener for investors and traders, financial visualizations.Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.
1. Ginkgo Bioworks. Ginkgo Bioworks is a biotech company that went public through a special purpose acquisition company last year. The company has the backing of Bill Gates and can design and ...Is Ginkgo Bioworks a stock worth buying? When the stock began trading in September 2021, its valuation was around $15 billion. Today, it has a market capitalization of just $3.2 billion.
Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($0.37) to ($0.30) per share. Ginkgo Bioworks has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 6th, 2024 based off prior year's report dates. Read More.
Establishing ownership of stock depends on how the stock was purchased, according to the Securities and Exchange Commission. A brokerage firm may have purchased the stock or it may have been bought directly from the company.Ginkgo Bioworks. Market Cap. $3B. Today's Change. (5.80%) $0.08. Current Price. $1.46. Price as of November 24, 2023, 1:00 p.m. ET. You’re reading a free article with opinions that may differ ...Nov 22, 2023 · The Ginkgo Bioworks stock price fell by -3.50% on the last day (Wednesday, 22nd Nov 2023) from $1.43 to $1.38. During the last trading day the stock fluctuated 8.82% from a day low at $1.36 to a day high of $1.48. The price has risen in 5 of the last 10 days but is still down by -7.38% for this period. Volume has increased on the last day by ... The Ginkgo Bioworks stock price fell by -3.50% on the last day (Wednesday, 22nd Nov 2023) from $1.43 to $1.38. During the last trading day the stock fluctuated 8.82% from a day low at $1.36 to a day high of $1.48. The price has risen in 5 of the last 10 days but is still down by -7.38% for this period. Volume has increased on the …Ginkgo Bioworks (DNA) added ~10% pre-market Tuesday after the company and Alphabet (GOOG) (GOOGL) unit Google Cloud announced a cloud and AI partnership. ... Stock is a screaming buy for sure at ...
Dec 4, 2023 · The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.
Dec 1, 2023 · 4 Wall Street research analysts have issued twelve-month price objectives for Ginkgo Bioworks' shares. Their DNA share price targets range from $1.25 to $3.00. On average, they anticipate the company's stock price to reach $2.25 in the next year. This suggests a possible upside of 58.5% from the stock's current price.
Boston-based Ginkgo Bioworks began trading on the New York Stock Exchange on Friday, becoming the latest company to close a SPAC merger and go public. Shares opened at $11.15 apiece under ticker ...Examples of gymnosperms are fir trees, spruce trees, pine trees, cycads and ginkgo trees. Examples of angiosperms include oak trees, maples, birches, forsythias, daisies, lilies and lilac bushes.Ginkgo Bioworks. Cathie Wood's Ark Invest is quickly building a position in a SPAC that plans to merge with Ginkgo Bioworks. The Ark Disruptive Innovation and Genomic Revolution ETFs doubled its ... Jul 25, 2022 · Ginkgo Bioworks acquired biotechnology firm Zymergen, the synthetic biology companies announced Monday morning, ... The all-stock deal values Zymergen at $300 million market capitalization, ... 3.90. Nikko Asset Management Americas, Inc. 3.67. ARK Genomic Revolution ETF. 3.25. The latest Ginkgo Bioworks Holdings stock prices, stock quotes, news, and …
They include Ginkgo Bioworks (DNA 1.59%), Monday.com (MNDY 3.37%), and Trimble (TRMB 1.50%). Let's find out a bit more about these three Cathie Wood stocks that are worth more consideration.News ; 17.11.2023. 3 Key Trends to Consider in Ginkgo Bioworks' Q3 Earnings Report ; 13.11.2023. 3 Cathie Wood Bargain Buys That Should Be on Your List Too ; 09.11 ...Jun 7, 2022 · Those are some eye-opening estimates, particularly since the leader in synthetic biomanufacturing, Ginkgo Bioworks (DNA 2.16%), currently has a market cap of $6 billion and trades for a little ... View the latest Ginkgo Bioworks Holdings Inc. (DNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.Ginkgo Bioworks (NYSE: DNA ), Twist Bioscience (NASDAQ: TWST ), and Amyris (NASDAQ: AMRS) all fell more than 75% from peak to trough, and may still have farther to fall. Still, improving monetary ...Last year was not a good one for Ginkgo Bioworks’ stock price, which dropped 80%. Ginkgo’s business model is that it wants to be the Apple (NASDAQ:AAPL) App Store of biotech, the one-stop-shop ...Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.
Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of 86.67% and 16.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead ...
Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Fiscal Q3 2023 ended 9/30/23. Reported on 11/8/23. Get the latest Ginkgo Bioworks Holdings Inc (DNA) real-time quote, historical performance, charts, and other financial information to help you... Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021.Fundamentally, Ginkgo Bioworks is a mixed bag with $478 million in 2022 revenues, up 52%, but $2.1 billion in net losses also. Still, at just over $1 per share, DNA stock is poised to more than ...Ginkgo Bioworks Holdings Inc stock has a Value Score of 6, Estimate Revisions Score of 34 and Quality Score of 13. Comparing Arcellx Inc and Ginkgo Bioworks Holdings Inc’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s …Ginkgo Bioworks reported Q2 revenue of $81 million, down 44% YoY, mainly due to a decline in Biosecurity revenue. Read more about DNA stock here.Mar 29, 2022 · Shares of Ginkgo Bioworks ( DNA 5.80%) were jumping 18.2% higher as of 10:58 a.m. ET. The nice gain came after the company announced its 2021 fourth-quarter and full-year results. Ginkgo reported ... Nov 29, 2023 · Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a leading hub in the biotechnology industry.
Find out the direct holders, institutional holders and mutual fund holders for Ginkgo Bioworks Holdings, Inc. (DNA).
Ginkgo Bioworks announces $100 million equity offering. Read more to see why it has been a very strange couple of days for DNA stock. Ginkgo Bioworks announces $100 million equity offering. Read ...
Feb 7, 2023 · 2. Ginkgo Bioworks. Ginkgo Bioworks (DNA 5.80%) is also a holding in the Ark Innovation ETF and the Ark Genomic Revolution ETF. The company is a leader in cell programming technology that's used ... Oct 06, 2021, 5:24 pm EDT. Shares of Ginkgo Bioworks Holdings closed down almost 12% after Scorpion Capital, a research firm focused on short selling, slammed the company as heavily reliant on ...With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.DNA | Complete Ginkgo Bioworks Holdings Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Shares of Ginkgo Bioworks ( DNA 5.80%) were jumping 18.2% higher as of 10:58 a.m. ET. The nice gain came after the company announced its 2021 fourth-quarter and full-year results. Ginkgo reported ...Ginkgo Bioworks' ( NYSE: DNA) first quarter results were something of a mixed bag, with continued progression on a number of metrics offset by rising costs and declining revenues. Ginkgo's success ...Aug 30, 2023 · Ginkgo Bioworks Holdings, Inc ... Buyers of the stock will need to have faith that Ginkgo can accelerate their business in the future as a PS of 12.5 for a company with operating margins of -228% ... Ginkgo Bioworks Holdings, Inc. provides horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals.2. Ginkgo Bioworks. Ginkgo Bioworks has scaled up the process of engineering organisms that can be used in a variety of industries, from agriculture to pharmaceuticals. Through the company's ...
Shares of Ginkgo Bioworks ( NYSE: DNA) added ~10% pre-market Tuesday after the cell platform company and Google Cloud, a unit of tech giant Alphabet Inc. ( NASDAQ: GOOG) ( NASDAQ: GOOGL ...Ginkgo Bioworks (NYSE:DNA) Is among the more prominent stocks in the synthetic biology space. The company is located in Boston, Massachusetts, which is a …1. Ginkgo Bioworks. Ginkgo Bioworks ( DNA) saw its shares fall by 69% over the last 12 months, but that could be just the opening that value-hunting investors need to start a position. Unlike ...Instagram:https://instagram. fsd pharmahow much is a 5 lb gold bar worthhow to get a home loan without tax returnsis zoominfo down Ginkgo Bioworks ( NYSE: DNA) is a leading synthetic biology company that went public through a SPAC in 2021. A large amount of hype has surrounded Ginkgo due to its ambitions, and it managed to ...First quarter 2023 Total revenue of $81 million, down from $168 million in the comparable prior year period, a decrease of 52% driven by the expected ramp down of K-12 testing in Ginkgo's ... nasdaq lntfidelity consumer staples etfneonode Nov 27, 2023 · Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. [Read more] In 2022, DNA's revenue was $477.71 million, an increase of 52.21% compared to the previous year's $313.84 million. Losses were -$2.10 billion, 15.0% more than in 2021. Dec 4, 2023 · The consensus among analysts is that Ginkgo Bioworks Holdings Inc (DNA) is a Hold stock at the moment, with a recommendation rating of 2.67. 1 analysts rate the stock as a Sell, while 0 rate it as Overweight. 4 out of 9 have rated it as a Hold, with 3 advising it as a Buy. 1 have rated the stock as Underweight.